Prognosis and Residual Tumor After Neoadjuvant Targeted Therapy in EGFR-Mutated Non-Small Cell Lung Cancer

What this Trial Is About

Researchers are studying lung cancer patients with a specific mutation called EGFR in their tumors. This type of non-small cell lung cancer NSCLC can respond well to targeted treatments given before surgery to shrink tumors and improve outcomes. The study looks back at patient data to understand how the amount of remaining live tumor residual viable tumor, RVT after this treatment relates to survival. The goal is to confirm RVTs value as a marker for predicting patient prognosis and guiding future care. This observational study involves patients who received targeted therapy before surgery and then had their tumors removed. Researchers examine the percentage of RVT left after treatment and surgery to see how it affects two main outcomes disease-free survival time without cancer returning and event-free survival time until relapse or death. They plan to follow patients for up to three years after surgery to collect this information. Participants will have their medical records and pathology reports reviewed to assess RVT and survival outcomes. The study includes patients aged 18 to 80 years who were diagnosed with EGFR-mutated NSCLC, treated with neoadjuvant targeted therapy, and underwent surgery. Researchers will analyze this data to better understand how RVT can help predict long-term results and improve management strategies for patients with this lung cancer subtype.

Association Between RVT and Prognosis After Neoadjuvant Targeted Therapy in EGFR NSCLC